4D Pharma PLC Final Results

4D pharma PLC (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, has today announced the final results for the Company and its subsidiaries (together “the Group”) for the year ended 31 December 2016.

 

Financial highlights for the year:

· Net assets of £86.5 million (2015: £92.7 million)

· Cash and cash equivalents (including cash on deposit) of £68.8 million (2015: £85.4 million)

· Loss after tax of £9.9 million (2015: £7.7 million)

· Loss per share (basic and diluted) of 15.2 pence (2015: 12.6 pence)

 

Operational highlights for the year:

· Successful phase 1 clinical trial in respect of Blautix, 4D’s proprietary programme for the treatment of Irritable Bowel Syndrome, achieving the primary objective of establishing safety and tolerability

· Analysis of patient data from phase 1 clinical trial showing a positive improvement in patient symptoms over placebo

· Analysis of IBS patient microbiome showing Blautix both stabilises and increases diversity of the microbiome

· Commencement of the phase 1 clinical trial in respect of Thetanix, 4D’s proprietary programme for the treatment of Paediatric Crohn’s Disease

· Acquisition of 4D Pharma Cork Limited (formerly Tucana Health Limited), a start-up company from University College Cork founded to investigate the use of microbiome signatures to aid the diagnosis and treatment of diseases; the year has also seen the successful development of its proprietary diagnostic platform, MicroDx, which uses microbiome signatures to allow patient stratification

· Acquisition of the production assets of Instituto Biomar, S.A. via a newly incorporated Spanish subsidiary, 4D Pharma León, S.L.U., establishing 4D’s own development and manufacturing facility in León, Spain

 

Following the year end:

· Interim analysis of data generated in the MicroDx clinical trial showing: significant differences between the microbiota profiles of IBS patients and healthy subjects; that microbiota of IBS clinical subtypes are not significantly different (supporting the rationale for Blautix as a therapy for all IBS subtypes); and that MicroDx is able to differentiate IBS patients from healthy subjects based on metabolite profiles

 

The Annual Report, together with a notice of the Company’s Annual General Meeting, will be posted to shareholders and made available on the Company’s website www.4dpharmaplc.com at a later date. The Annual General Meeting will be held on Friday 26 May 2017 at 1 p.m. at the Gridiron Building, 1 Pancras Square, London N1C 4AG.

 

David Norwood, Chairman of 4D, commented: I am pleased to be able to announce the Group’s final results for the year ended 31 December 2016. The year has seen substantial and critical advances towards our goal of producing Live Biotherapeutics as safe and effective therapies: successfully concluding our first clinical trial; generating supportive clinical data; establishing our proprietary diagnostic platform; and acquiring our own development and manufacturing facility. I would like thank everyone in the Group for their contribution to the advances we have made in 2016.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    4d Pharma Plc

    More articles like this

    4d Pharma Plc

    People with fibromyalgia have different gut bacteria

    A study that compared women with and without fibromyalgia has, for the first time, linked gut bacteria to the long-lasting disease and its main symptoms. Researchers in Canada identified 19 species of gut bacteria that were

    4d Pharma Plc

    Findings link gut bacteria and Fibromyalgia

    Fibromyalgia affects 2-4 percent of the population and has no known cure. Symptoms include fatigue, impaired sleep, and cognitive difficulties, but the disease is most clearly characterized by widespread chronic pain. As reported in the journal Pain,

    4d Pharma Plc

    Gut bacteria: The surprising impact of viruses

    The microbiome plays a vital role in health. A recent study has investigated how viruses that kill gut bacteria influence these microbes. The findings make an already complicated picture much more so. The microbiome is both

    4d Pharma Plc

    4D pharma plc Presents MRx0518 combination study at ASCO

    4D pharma plc (LON: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announced the presentation of a poster detailing its Phase I/II clinical study of MRx0518 combined with KEYTRUDA® in patients with solid

    4d Pharma Plc

    4D pharma plc Directors purchase more shares in company

    4D pharma plc (LON: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, has today announced that David Norwood, Duncan Peyton and Alex Stevenson have purchased ordinary shares in the Company as listed below. Following this transaction,

    4d Pharma Plc

    4D pharma plc Presents Phase Ib Clinical Data on Thetanix

    4D pharma plc (LON: DDDD), a pharmaceutical company focusing on the development of Live Biotherapeutics, today announced that data from the completed Phase Ib clinical study of Thetanix® for the treatment of Crohn’s disease will be

    4d Pharma Plc

    Can this food additive turn our gut bacteria against us?

    E171 is a food additive that manufacturers use to whiten various products, including chewing gum, cake icing, and candy, for instance. While the addition of this substance may render certain products more appealing, there is an

    4d Pharma Plc

    7 Things Doctors Want You To Know About IBS

    Irritable bowel syndrome, or IBS, is one of those health conditions that can be difficult to talk about. And when you are struggling with things like diarrhea, constipation, gas, and bloating, it’s completely understandable. But there

    4d Pharma Plc

    4D pharma plc Participation in Microbiome Conference

    4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces its participation in the inaugural Chardan Capital Markets LLC Microbiome Medicines Summit. Alex Stevenson, 4D’s Chief Scientific Officer, gave a